Relationship Between Haemagglutination-inhibiting Antibody Titres and Clinical Protection Against Influenza: Development and Application of a Bayesian Random-effects Model

Overview

Journal BMC Med Res Methodol

Publisher Biomed Central

Specialties General Medicine
Health Services

Date 2010 Mar 10

PMID 20210985

Citations 189

Authors

Laurent Coudeville

Fabrice Bailleux

Benjamin Riche

Francoise Megas

Philippe Andre

Rene Ecochard

Affiliations

Soon will be listed here.

Abstract

Background: Antibodies directed against haemagglutinin, measured by the haemagglutination inhibition (HI) assay are essential to protective immunity against influenza infection. An HI titre of 1:40 is generally accepted to correspond to a 50% reduction in the risk of contracting influenza in a susceptible population, but limited attempts have been made to further quantify the association between HI titre and protective efficacy.

Methods: We present a model, using a meta-analytical approach, that estimates the level of clinical protection against influenza at any HI titre level. Source data were derived from a systematic literature review that identified 15 studies, representing a total of 5899 adult subjects and 1304 influenza cases with interval-censored information on HI titre. The parameters of the relationship between HI titre and clinical protection were estimated using Bayesian inference with a consideration of random effects and censorship in the available information.

Results: A significant and positive relationship between HI titre and clinical protection against influenza was observed in all tested models. This relationship was found to be similar irrespective of the type of viral strain (A or B) and the vaccination status of the individuals.

Conclusion: Although limitations in the data used should not be overlooked, the relationship derived in this analysis provides a means to predict the efficacy of inactivated influenza vaccines when only immunogenicity data are available. This relationship can also be useful for comparing the efficacy of different influenza vaccines based on their immunological profile.

Citing Articles

Adenoviral-Vectored Multivalent Vaccine Provides Durable Protection Against Influenza B Viruses from Victoria-like and Yamagata-like Lineages.

Pekarek M, Madapong A, Wiggins J, Weaver E Int J Mol Sci. 2025; 26(4).

PMID: 40004004 PMC: 11855595. DOI: 10.3390/ijms26041538.

Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.

Ge Y, Handel A, Giabbanelli P, Lemacks J, Greer T, Raynee P Vaccine. 2025; 49:126802.

PMID: 39908720 PMC: 11875013. DOI: 10.1016/j.vaccine.2025.126802.

Dynamics of influenza transmission in vampire bats revealed by longitudinal monitoring and a large-scale anthropogenic perturbation.

Griffiths M, Broos A, Morales J, Tu I, Bergner L, Behdenna A Sci Adv. 2025; 11(6):eads1267.

PMID: 39908385 PMC: 11797540. DOI: 10.1126/sciadv.ads1267.

Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.

Zhao Y, Liu J, Peng C, Guo S, Wang B, Chen L J Nanobiotechnology. 2025; 23(1):77.

PMID: 39905416 PMC: 11792681. DOI: 10.1186/s12951-025-03122-6.

The Impact of Obesity on Influenza Vaccine Immunogenicity and Antibody Transfer to the Infant During Pregnancy.

Clarke M, Mathew S, Giles L, Barr I, Richmond P, Marshall H Vaccines (Basel). 2025; 12(12.

PMID: 39771969 PMC: 11680122. DOI: 10.3390/vaccines12121307.

References

Clark A, POTTER C, Jennings R, Nicholl J, Langrick A, Schild G . A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond). 1983; 90(3):351-9. PMC: 2134273. DOI: 10.1017/s0022172400028989. View

POTTER C, Jennings R, Nicholson K, Tyrrell D, Dickinson K . Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond). 1977; 79(3):321-32. PMC: 2129958. DOI: 10.1017/s0022172400053158. View

Nauta J, Beyer W, Osterhaus A . On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals. 2009; 37(4):216-21. DOI: 10.1016/j.biologicals.2009.02.002. View

Goodeve A, POTTER C, Clark A, Jennings R, Schild G, YETTS R . A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond). 1983; 90(1):107-15. PMC: 2134195. DOI: 10.1017/s0022172400063907. View

Dowdle W, Coleman M, Mostow S, KAYE H, Schoenbaum S . Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J. 1973; 49(569):159-63. PMC: 2495389. DOI: 10.1136/pgmj.49.569.159. View

Greenberg S, Couch R, KASEL J . An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness. Am J Epidemiol. 1974; 100(3):209-15. DOI: 10.1093/oxfordjournals.aje.a112029. View

MEIKLEJOHN G, WEISS D, SHRAGG R, LENNETTE E . Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination. Am J Hyg. 1952; 55(1):1-11. DOI: 10.1093/oxfordjournals.aje.a119498. View

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

Hirota Y, Kaji M, Ide S, Kajiwara J, Kataoka K, Goto S . Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine. 1997; 15(9):962-7. DOI: 10.1016/s0264-410x(96)00302-7. View

10.

de Jong J, Palache A, Beyer W, Rimmelzwaan G, Boon A, Osterhaus A . Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel). 2004; 115:63-73. View

11.

Wood J, Gaines-Das R, Taylor J, Chakraverty P . Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994; 12(2):167-74. DOI: 10.1016/0264-410x(94)90056-6. View

12.

Qin L, B Gilbert P, Follmann D, Li D . ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. Ann Appl Stat. 2008; 2(1):386-407. PMC: 2601643. DOI: 10.1214/07-AOAS132. View

13.

De Gruttola V, Clax P, DeMets D, Downing G, Ellenberg S, Friedman L . Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001; 22(5):485-502. DOI: 10.1016/s0197-2456(01)00153-2. View

14.

Clark A, POTTER C, Jennings R, Nicholl J, Langrick A, Schild G . A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J Hyg (Lond). 1983; 90(3):361-70. PMC: 2134281. DOI: 10.1017/s0022172400028990. View

15.

Plotkin S . Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001; 20(1):63-75. DOI: 10.1097/00006454-200101000-00013. View

16.

Qin L, B Gilbert P, Corey L, McElrath M, Self S . A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis. 2007; 196(9):1304-12. DOI: 10.1086/522428. View

17.

Beyer W, Palache A, Luchters G, Nauta J, Osterhaus A . Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res. 2004; 103(1-2):125-32. DOI: 10.1016/j.virusres.2004.02.024. View

18.

Evans A . Serologic studies of acute respiratory infections in military personnel. Yale J Biol Med. 1975; 48(3):201-9. PMC: 2595222. View

19.

Hannoun C, Megas F, Piercy J . Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004; 103(1-2):133-8. DOI: 10.1016/j.virusres.2004.02.025. View

20.

Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H . The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2003; 1(1):49-67. DOI: 10.1093/biostatistics/1.1.49. View